WCWTPs2e2: What do we know about the "nocebo effect" and how it works?
[iframe style="border:none" src="//html5-player.libsyn.com/embed/episode/id/5117781/height/100/width/480/thumbnail/no/render-playlist/no/theme/standard-mini/tdest_id/448900" height="100" width="480" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen] Welcome to Season 2, Episode 2 of the show. Who cares? What's the point? The podcast about the mind for people who think.
If you're a regular listener - welcome back.If you're new to the show, welcome to you too. Please check out the shows in Season 1 - I hope you'll find some interesting conversation in the 10 shows we have in our back catalogue.
If you do enjoy this episode, and would like to support the show, you can do that in a few ways:
You can donate the cost of a cup of coffee at tinuurl.com/wcwtp until March 17, 2017. This helps me to meet some of the hosting costs for the show and to help develop the show a little further.
You can also leave a review on iTunes - that really helps others to find the show.
In this episode, I talk with Rebecca Webster who is based at King's College in the University of London, UK. In this conversation, we focus on Rebecca's work on s systematic review on the 'nocebo effect' - what it is and how it might work. We also talk about what researchers mean when they talk about a systematic review.
Here is the link to the paper we talk about in this week's show:
And fortunately, you can find the full paper at this link too.
Here is the abstract for some context:
Objectives: Medication side effects are common, often leading to reduced quality of life, nonadherence, and financial costs for health services. Many side effects are the result of a psychologically mediated "nocebo effect." This review identifies the risk factors involved in the development of nocebo effects. Method: Web of Science, Scopus, MEDLINE, PsycINFO, Journals@Ovid full text, and Global Health were searched using the terms "nocebo" and "placebo effect." To be included, studies must have exposed people to an inert substance and have assessed 1 or more baseline or experimental factor(s) on its ability to predict symptom development in response to the inert exposure. Results: Eighty-nine studies were included; 70 used an experimental design and 19 used a prospective design, identifying 14 different categories of risk factor. The strongest predictors of nocebo effects were a higher perceived dose of exposure, explicit suggestions that the exposure triggers arousal or symptoms, observing people experiencing symptoms from the exposure, and higher expectations of symptoms. Conclusions: To reduce nocebo induced symptoms associated with medication or other interventions clinicians could reduce expectations of symptoms, limit suggestions of symptoms, correct unrealistic dose perceptions, and reduce exposure to people experiencing side effects. There is some evidence that we should do this especially for persons with at-risk personality types, though exactly which personality types these are requires further research. These suggestions have a downside in terms of consent and paternalism, but there is scope to develop innovative ways to reduce nocebo effects without withholding information.
I hope you find our conversation interesting and thought-provoking.
I'd love some feedback from you about the show.
You can follow the show on twitter @wcwtp, and find the website at whocareswhatsthepoint.com
You can also email the show at firstname.lastname@example.org
Please feel free to share the link to the show with your friends and colleagues. You can subscribe here or via this iTunes link:https://itunes.apple.com/us/podcast/who-cares-whats-the-point/id1179662350?mt=2
Or on Stitcher too: http://www.stitcher.com/podcast/who-cares-whats-the-point?refid=stpr